Stemirna Therapeutics Completed Nearly 100 Million Yuan A Round of Financing

According to VCBeat, Stemirna Therapeutics completed nearly 100 million yuan A round of financing in July 2019, the investors include Zhangjiang Torch Venture Capital, Zhuhai Longmen No.3, Jiuyou Wisdom, Yitai Jiuyou and Fanghua Investment. The angel round investor Longpan Investment made additional investment, and Tanzhen capital served as the current round of financial advisor.

It is known that this round of financing will be used to build a mRNA medical GMP production center, and carry out clinical trials in three hospitals and IND declaration of personalized tumor vaccine projects. Stemirna Therapeutics will simultaneously advance the preliminary study of follow-up work.

Using the latest mRNA technology, the personalized mRNA vaccine for tumors which is specially against neoantigen has become an effective treatment for individualized treatment of cancer patients.

The mRNA vaccine of Stemirna Therapeutics using the mRNA fragments which encoded outside the human body, then packaged them in nanomaterials, delivering to human cells to complete the subsequent translation process in the human body. It will express a patient-specific new antigen to arouse the immune system, and make the immune system recognize and kill tumor cells which carry new antigens. 

Founded in 2016, Stemirna Therapeutics is a high-tech biotechnology company whose core team including returning PhDs of MD Anderson Cancer Center based in Zhangjiang Free Trade Zone, Pudong, Shanghai. The company’s aim is to build a comprehensive mRNA therapeutic industrial chain includes an mRNA drug platform, a GMP production center, a tumor neoantigen library and an mRNA drug clinical cooperation platform. With its unique technology platform advantages, it is the first and only platform-based mRNA research and develop enterprise in China.

Zhangjiang Torch Venture Capital is a state-owned financial investment company established in Shanghai in 2008.